Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta, Inc. (NASDAQ: AZTA) is a global leader in providing advanced life sciences solutions, empowering breakthrough therapies and expediting their market reach. Headquartered in Burlington, MA, Azenta operates across North America, Europe, and Asia, catering to top pharmaceutical, biotech, academic, and healthcare institutions worldwide.
Azenta offers a comprehensive array of reliable cold-chain sample management solutions and genomic services, spanning critical areas such as drug development, clinical research, and advanced cell therapies. The company’s core business is divided into two segments: Life Sciences Products and Life Sciences Services, with the latter being the primary revenue driver.
Recent achievements highlight Azenta's robust financial health and strategic initiatives. In the fourth quarter of fiscal 2023, the company delivered impressive results amidst challenging economic conditions, underscored by robust cost reduction programs and strategic investments in its sales force. This progress translates into a promising outlook for fiscal 2024, with expected organic revenue growth of 5 to 8%, continued margin expansion, and positive free cash flow.
Azenta's commitment to driving long-term shareholder value is evident through its planned $500 million share repurchase initiative for fiscal 2024. This underscores the company's strong balance sheet and ample liquidity, which includes approximately $500 million in available cash for strategic investments.
Key partnerships and expansions further solidify Azenta's industry footprint. The recent opening of a new Genomics Laboratory in Oxford, UK, enhances its reach, providing local researchers with advanced next-generation sequencing technologies and expertise. Additionally, Azenta has been selected by the Crohn's & Colitis Foundation to manage sample services for significant research cohorts, emphasizing its pivotal role in advancing precision medicine.
Azenta’s portfolio showcases industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems, which deliver essential support and innovation in life sciences research and development.
The company is also noted for its prudent use of non-GAAP financial measures, providing investors with a clear perspective on operational results relative to industry peers. These measures complement traditional GAAP results by adjusting for items like amortization of intangible assets and restructuring charges, offering a more comprehensive view of financial performance.
As Azenta continues to navigate its transformational journey, including a CEO succession plan aimed at sustaining growth and innovation, it remains committed to its mission of accelerating impactful therapies and supporting the global scientific community.
Azenta, Inc. (Nasdaq: AZTA) announced a $500 million accelerated share repurchase (ASR) agreement with JP Morgan Chase Bank to enhance shareholder value. This ASR is part of a larger $1.5 billion share repurchase authorization, with an additional $500 million planned for repurchases over the next year. The initial delivery will be approximately 6.1 million shares on November 28, 2022, and the final settlement is expected by June 30, 2023. The ASR aims to optimize capital allocation and boost earnings per share (EPS).
Azenta, Inc. (Nasdaq: AZTA) reported expected Q4'22 revenue of $138 million, marking no change year-over-year, with a 30% growth forecast for fiscal 2023. Excluding COVID impacts, organic growth reached 12% in Q4 and 17% for the year. The Board of Directors authorized a $1.5 billion share repurchase program, intending to buy back at least $1 billion of common stock. Despite a diluted EPS of ($0.07), management noted strong performance in life sciences services and a focus on growth alongside an acquisition of B Medical Systems.
Azenta, Inc. (Nasdaq: AZTA) has nominated Tina S. Nova, Ph.D., and Dorothy E. Puhy for election to its Board of Directors during the 2023 Annual General Meeting. Both nominees will join the Board as non-voting observers immediately. Nova brings over 25 years of experience in life sciences, previously leading companies that engaged in significant acquisitions, including Decipher Biosciences. Puhy, with extensive expertise from her tenure at Dana-Farber Cancer Institute, has held key leadership roles. This Board refreshment aims to enhance Azenta's strategic direction and support its transformation efforts.
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the Stephens Annual Investment Conference in Nashville, Tennessee on November 16, 2022. The presentation will start at 12:00 pm CT and can be accessed via a live webcast on Azenta's investor relations website. A replay will also be available post-event. Azenta provides comprehensive life sciences solutions, including cold-chain sample management and genomic services, supporting pharmaceutical and biotech sectors globally. For more details, visit Azenta's website.
Azenta, Inc. (Nasdaq: AZTA) and the Government of Luxembourg signed a Memorandum of Understanding (MoU) to enhance healthcare technology development in Luxembourg. This agreement, signed by Minister of Economy Franz Fayot and Azenta CEO Steve Schwartz, supports continued operations of B Medical Systems—recently acquired by Azenta. The MoU aims to foster collaboration on future research and innovation initiatives. Minister Fayot emphasized the importance of this partnership in showcasing Luxembourg's health technology sector. Azenta plans to leverage its global network to expand B Medical Systems' market reach.
Azenta, Inc. (Nasdaq: AZTA) will release its fiscal Q4 and full year 2022 earnings on November 14, 2022, after market close. A conference call will follow at 4:30 p.m. ET for analysts and investors, with access via phone and a live webcast on Azenta's website. The firm specializes in life sciences solutions and has recently rebranded from Brooks Automation. Azenta is focused on cold-chain sample management, drug development, and advanced cell therapies, operating globally across North America, Europe, and Asia.
Azenta, Inc. (Nasdaq: AZTA) completed the acquisition of B Medical Systems, a leader in temperature-controlled storage and transportation solutions, enhancing Azenta's cold chain capabilities. This strategic move allows Azenta to deliver life-saving treatments to over 150 countries, addressing emerging market needs for reliable storage and transport. With a base of 500,000 units, B Medical offers real-time monitoring and tracking. The acquisition aims to leverage Azenta's expertise and expand its market reach in North America and Europe.
Azenta, Inc. (Nasdaq: AZTA) will participate in the Baird 2022 Global Healthcare Conference in New York City on September 14, 2022, with a presentation starting at 9:40 am ET. The event will be accessible via live webcast on Azenta's investor relations website, with a replay available post-event. Azenta is a provider of life sciences solutions, focusing on cold-chain sample management and genomic services for pharmaceutical and biotech sectors. The company rebranded from Brooks Automation, Inc. to Azenta, Inc. on December 1st.
Azenta, Inc. (Nasdaq: AZTA) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York City on September 13, 2022. The presentation is scheduled for 4:40 pm ET and can be accessed via their investor relations website. A replay will be available post-event. Azenta offers comprehensive life sciences solutions, facilitating faster market breakthroughs in drug development and clinical research. The company, headquartered in Chelmsford, MA, transitioned its name and ticker from Brooks Automation to Azenta in December 2021.
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16, 2022. The company, which recently rebranded from Brooks Automation, offers comprehensive life sciences solutions, enhancing drug development and clinical research efforts globally. Azenta specializes in cold-chain sample management and genomic services, supporting leading pharmaceutical and biotech firms.
Headquartered in Chelmsford, MA, Azenta operates in North America, Europe, and Asia. For more details, visit www.azenta.com.
FAQ
What is the current stock price of Azenta (AZTA)?
What is the market cap of Azenta (AZTA)?
What does Azenta, Inc. specialize in?
Where is Azenta headquartered?
What are Azenta's main business segments?
What recent financial achievements has Azenta reported?
What notable partnerships has Azenta recently formed?
How does Azenta support the life sciences industry?
What brands are encompassed within Azenta’s portfolio?
What is Azenta’s strategy for shareholder value?
How does Azenta use non-GAAP financial measures?
Who is involved in Azenta’s CEO succession plan?
